According to the WeChat news of the National Health Insurance Administration, as of December 31, 2023, a total of 26 pharmaceutical companies have been rated as "particularly serious" and "serious" dishonesty. So, why are these companies assessed as dishonest? What are the specific acts of untrustworthiness? What is the impact of the dishonesty assessment on the enterprise? The person in charge of the relevant department of the National Health Insurance Administration gave a detailed introduction to the relevant situation in an interview.
The main reason for these enterprises to be assessed as untrustworthy is that they have drug kickbacks, monopoly price increases, and disrupted procurement order, which violate the market rules of fairness and legality, honesty and trustworthiness, and consistent quality and price. According to the documents previously released by the National Health Insurance Administration, for these untrustworthy behaviors, the credit rating will be assessed according to the severity of the circumstances, and the qualification for online procurement will be suspended if it reaches a certain level.
The pharmaceutical** and procurement credit evaluation system divides the untrustworthy behavior of enterprises into four levels: "general", "moderate", "serious" and "particularly serious". For example, for drug rebates, the cumulative or single bribe amount of more than 500,000 yuan but less than 2 million yuan is considered "serious" untrustworthiness, while the cumulative or single bribe amount of more than 2 million yuan is "particularly serious" untrustworthiness.
The assessment of untrustworthy conduct will have varying degrees of impact on enterprises. Generally, dishonest enterprises will be reminded and admonished in writing; Moderately untrustworthy enterprises will be substantially affected, such as marking untrustworthy information on the provincial pharmaceutical procurement platform, medical institutions will receive risk warnings when placing orders for procurement; Seriously untrustworthy enterprises will face stricter restrictive measures, such as suspending the qualifications for listing, bidding or distribution of specific products involved in the case; Enterprises with particularly serious dishonesty will face the restrictive measures of suspending all drug consumables from being listed on the Internet, bidding or distribution qualifications in the province where the case occurred.
For dishonest enterprises, the National Health Insurance Administration emphasizes that "punishment" is not the goal, but more importantly, it is more important to guide enterprises to standardize their behavior and protect the legitimate rights and interests of the insured. The system also provides a clear path for untrustworthy enterprises to make corrections, such as repairing credit through practical actions such as price reductions and price refunds.
To sum up, the standardized development of the pharmaceutical market is inseparable from the integrity management of enterprises and the strict supervision of regulatory authorities. Only by establishing a market order of fair competition can we ensure the healthy development of the pharmaceutical industry. This news has triggered us to think about the norms of the pharmaceutical market, how can enterprises adhere to integrity in the competition? How can regulators better maintain market order? Welcome to leave a message to discuss.